Genital Chlamydia trachomatis infection is a significant public health burden; Professor of Pediatrics and Microbiology and ...

Revenue: Revenue for the three months ended September 30, 2024, increased to approximately $1,958,000 compared to $397,000 ...

Evaxion Biotech (EVAX) announces new positive preclinical data from its ongoing cytomegalovirus, CMV, vaccine program named EVX-V1. The data ...

The company aims to create earlier treatment options for multiple solid tumor types and is strengthening its clinical development pipeline following two complementary approaches: off-the-shelf cancer ...

New preclinical data demonstrates that CMV antigens identified with Evaxion's AI-Immunology platform trigger targeted immune responses Results also showcase the successful design of a proprietary pref ...

About 1 in 200 babies is born with congenital CMV infection and the virus infects approximately 60% to 70% of adults in developed countries. No approved CMV vaccine exists today ...

Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, announces that key opinion leader (“ KOL ”) collaborators are presenting results ...

To improve long-term persistence and reduce the risk of immune rejection, researchers are exploring ways to diminish the ...

Mycoplasma Plate Antigens Market. The global mycoplasma plate antigens market, valued at USD 465 million in 2021, is set to experience robust growth, according to recent market an ...

A2 Bio shares clinical study progress and the increased diversity of participants in the BASECAMP-1 prescreening study during ...